Study Published in Dermatologic Therapy Shows Efficacy of Sensus Healthcare’s SRT Combined with Punch Excision to Treat Keloids

Audio By Carbonatix

BOCA RATON, Fla.--(BUSINESS WIRE)--Sep 23, 2025--

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that a study published in Dermatologic Therapy demonstrates the safety and efficacy of the Company’s superficial radiotherapy (SRT) technology combined with punch excision to treat keloids.

The article, titled “ Efficacy of Punch Excision Combined With Superficial X-Ray for the Treatment of Keloids: A Single-Center Retrospective Study,” evaluates 60 patients treated with a combination of punch excision and superficial X-ray therapy at the Hospital for Skin Diseases in Nanjing, China. The punch excision better enables SRT penetration to induce fibroblast apoptosis, yielding a synergistic therapeutic effect. Results showed a statistically significant improvement in patient outcomes, with notable reductions in pain, itching, thickness and irregularity of keloid scars after one year of follow-up. No severe adverse reactions were reported, reinforcing the safety profile of SRT.

“This study by Junyou Zheng and colleagues is one of very few to examine punch excision combined with SRT, and it supports existing literature showing the benefits of our SRT technology in preventing keloid recurrence following surgical excision. The psychological impact of keloids is not to be underestimated, and this study underscores keloids as a serious medical condition that warrants access to treatment, including combination therapy with SRT,” said Joe Sardano, Chairman and CEO of Sensus Healthcare. “Superficial radiotherapy has a long-standing record of safety, efficacy and patient satisfaction, and we believe studies such as this one will play an important role in shaping payer and policymaker understanding of the significant physical and emotional burden keloids place on patients.”

“This study extends the safe and effective use of superficial radiation beyond post complete surgical keloid excision to following punch excision keloid debulking, allowing for treatment of multiple and extensive keloids. This technique was found to be highly statistically significantly effective, by both investigator (VSS) and patient (POSAS) validated scoring scales,” commented Brian Berman, M.D., Ph.D., Professor of Dermatology at The University of Miami Miller School of Medicine and member of the Board of Directors of the American Academy of Dermatology.

Keloids are benign skin tumors that develop due to an abnormal overgrowth of scar tissue, and can cause significant pain, itching and emotional distress. Traditional treatment options, including corticosteroid injections, cryotherapy and laser therapy, often yield inconsistent results and are associated with high rates of recurrence. While often misunderstood as a cosmetic concern, keloids represent a serious medical condition with a population prevalence of 4% to 16%. They occur most frequently among individuals with higher levels of melanin, including people of African descent, as well as Hispanic and Asian populations.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Forward-Looking Statements

This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250923958474/en/

CONTACT: Alliance Advisors IR

Tirth T. Patel

[email protected]

212-201-6614

KEYWORD: UNITED STATES NORTH AMERICA FLORIDA

INDUSTRY KEYWORD: ONCOLOGY MEDICAL DEVICES HEALTH HEALTH TECHNOLOGY OTHER HEALTH GENERAL HEALTH

SOURCE: Sensus Healthcare, Inc.

Copyright Business Wire 2025.

PUB: 09/23/2025 08:00 AM/DISC: 09/23/2025 07:59 AM

http://www.businesswire.com/news/home/20250923958474/en